Heart health in adults with multiple myeloma starting new treatment
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at heart health in adults with multiple myeloma who are starting a new treatment. It aims to see how the treatment affects the heart and to help manage any heart-related risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of multiple myeloma.
- You must be 18 years old or older.
- You must be getting ready to start a new line of treatment for your multiple myeloma (whether it's your first treatment or a subsequent one).
- You must be able to attend follow-up visits at 3, 6, and 12 months.
- You must not have an acute heart condition that requires emergency care.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a new heart ultrasound test can measure heart side effects and overall outcomes in people with multiple myeloma who are treated with the RVd drug combination. It may help doctors better understand heart risks during treatment.
This study tests if a plant-based diet can help people with newly diagnosed multiple myeloma who are receiving a standard 4-cycle drug combination (DRVd). Researchers want to see if changing what you eat might improve treatment results.
This trial is testing whether aspirin or a blood thinner called rivaroxaban can best prevent harmful blood clots in people newly diagnosed with multiple myeloma who have a high risk of developing clots. It aims to find a safer and more effective way to protect you during treatment.
This trial tests a personalized treatment approach for people aged 65 and older with newly diagnosed multiple myeloma. The goal is to tailor therapy based on each patient's level of frailty, which could help improve outcomes and reduce side effects.
This study looks at how blood thinners are used in people with newly diagnosed multiple myeloma. The goal is to find better ways to prevent blood clots during treatment.
This study looks at whether people with newly diagnosed multiple myeloma can safely continue or adjust treatment after they reach “MRD-negative,” meaning very low signs of disease in the bone marrow. It may help reduce the chance of relapse while avoiding unnecessary treatment for some patients.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.